Search clinical trials for: Antibody Dependent Cellular Cytotoxicity (ADCC)

Total 12004 results

National Cancer Institute (NCI)

Completed

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

Mycosis Fungoides | Sezary Syndrome | Adult T-Cell Lymphoma/Leukemia

United States
Hangzhou Cancer Hospital
Shanghai bokang bioengineering co., LTD

Unknown

Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

Advanced Cancer | ADCC | NK Cell Mediated Immunity | Nimotuzumab | Adaptive Transfer

China
National Cancer Institute (NCI)

Terminated

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Clear-Cell Renal Carcinoma

United States
National University Hospital, Singapore

Unknown

ADCC Against Gastric Cancer Cells

Gastric Cancer

Singapore
University of Arizona
Mayo Clinic; National Institutes of Health (NIH); National Institute on Aging... and other collaborators

Recruiting

Alzheimer's Disease Core Center (ADCC)

Mild Cognitive Impairment | Alzheimer's Disease | Age-Related Memory Disorders

United States
Wake Forest University Health Sciences

Recruiting

Wake Forest Alzheimer's Disease Clinical Core (ADCC)

Prediabetic State | Mild Cognitive Impairment | Alzheimer's Disease

United States
University of Bath
University of Southampton; Royal United Hospitals Bath NHS Foundation Trust; Great...

Completed

Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia

Chronic Lymphocytic Leukemia | Minimal Residual Disease

United Kingdom
Yuehua Huang

Completed

A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)

Hepatocellular Carcinoma

China
Tokhirbek Dolimov

Unknown

Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta

Chronic Hepatitis Delta | Liver Biopsy

Uzbekistan
Centre Leon Berard
Amgen

Recruiting

Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (BREASTIMMU02)

HER2-positive Breast Cancer | Operable Breast Cancer

France
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.; Teva Pharma

Completed

Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

Adenocarcinoma of the Pancreas | Solid Tumour | Adenocarcinoma of the Colorectal
National Cancer Institute, Naples

Recruiting

Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (CIFRA)

Colorectal Cancer | ADCC

Italy
Novartis Pharmaceuticals

Active, not recruiting

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER)

Autoimmune Hepatitis

United States, Belgium, Germany, United Kingdom, Spain, Switzerland, Argentina, Canada, Japan, Czechia
Institut de Cancérologie de la Loire
Saint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand Paris

Withdrawn

Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers (IRAM)

Metastatic Colorectal Cancer | Metastatic Breast Cancer | Metastatic Head and Neck Cancer

France
National Cancer Institute (NCI)

Completed

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

Mycosis Fungoides | Sezary Syndrome | Anaplastic Large Cell Lymphoma | Peripheral T-cell Lymphoma NOS

United States
National Cancer Institute (NCI)

Terminated

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Leukemia | Chronic | Lymphocytic | B-Cell

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (ADCC)

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell... and other conditions

United States
Research Institute of Epidemiology, Microbiology...

Active, not recruiting

Possible Association of Intestinal Helminths and Protozoa With Colorectal Cancer Pathogenesis

Protozoan Infections | Colorectal Cancer | Colorectal Cancer Metastatic | Intestinal Parasite
National University Hospital, Singapore
National University of Singapore

Unknown

Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

Non-Hodgkin's Lymphoma | B-Cell Chronic Lymphocytic Leukemia

Singapore
Biohaven Pharmaceuticals, Inc.
Dana-Farber Cancer Institute

Recruiting

Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients

Multiple Myeloma

United States
NYU Langone Health
Bristol-Myers Squibb; Daiichi Sankyo, Inc.

Completed

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Novartis Pharmaceuticals

Recruiting

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Squamous Cell Carcinoma of Head and Neck | Esophageal Squamous Cell Carcinoma

Japan, France, Italy, Spain, Belgium, Germany, Taiwan, United States, Singapore
Fate Therapeutics

Completed

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | HER2 Positive Gastric Cancer | EGFR Positive Solid Tumor

United States
NKGen Biotech, Inc.
Affimed GmbH

Terminated

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Squamous Cell Carcinoma of Head and Neck | Advanced Solid Tumor | Metastatic Tumor | Refractory Tumor

United States
Masonic Cancer Center, University of Minnesota

Withdrawn

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

HIV-1-infection | ART | Interleukin | Cd4+ Lymphocyte Deficiency | Lymphoid Tissue; Infection

United States
AstraZeneca

Completed

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United Kingdom, United States, Italy, Spain, Germany, France
Pega-One S.A.S.
ICON plc

Withdrawn

Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)

Cutaneous Squamous Cell Carcinoma
National Cancer Institute (NCI)

Completed

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Peripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)

United States
Dartmouth-Hitchcock Medical Center
Amgen

Terminated

Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function

Metastatic Breast Cancer
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Multiple Myeloma

United States
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Multiple Myeloma

United States
Imperial College London

Active, not recruiting

Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens (EAVI2020_01)

HIV-1-infection

United Kingdom
Imperial College London
Bill and Melinda Gates Foundation

Completed

Optimising DNA Vaccinations in Healthy Volunteers (DNAVAC001)

HIV-1-infection
Regeneron Pharmaceuticals

Not yet recruiting

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body (FERVENT-1)

Non-transfusion Dependent Beta-thalassemia (NTDT)
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) (BAH242)

Autoimmune Diseases | Systemic Lupus Erythematosus | Systemic Sclerosis | Lupus Nephritis | Microscopic Polyangiitis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Sjogren's Syndrome | Idiopathic Inflammatory Myopathies | Granulomatous Polyangiitis

China
Guangzhou FineImmune Biotechnology Co., LTD.

Recruiting

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors (TAL-T)

Advanced Solid Tumor | Immunotherapy | Tumor Associated Lymph Node T Cell

China
Sana Biotechnology

Recruiting

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) (GLEAM)

Systemic Lupus Erythematosus | Microscopic Polyangiitis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Lupus Erythematosus | SLE (Systemic Lupus) | Granulomatous Polyangiitis

United States
Kanglin Biotechnology (Hangzhou) Co., Ltd.

Not yet recruiting

A Phase I/II Clinical Study of the KL003 Cell Injection in β-Thalassemia Major Participants

Transfusion-dependent Beta-Thalassemia

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
Institute of Hematology & Blood Diseases Hospital...
Kanglin Biotech

Recruiting

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

Transfusion-dependent Beta-Thalassemia

China
Merck Sharp & Dohme LLC
GOG Foundation; European Network for Gynaecological Oncological Trial groups(ENGOT)

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Endometrial Cancer

Poland, Canada, Australia, Israel, Korea, Republic of, United States, Spain, Chile, France, Puerto Rico, Greece, Netherlands, Norway, Singapore, Switzerland, Argentina, Austria, Belgium, Czechia, Denmark, Finland, Malaysia, Sweden, Italy and more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Breast Neoplasms

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Breast Neoplasms

China
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

China, Taiwan, United States, Australia, Israel, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia, Thailand
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Sintilimab | Lenvatinib

China
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Camrelizumab | Lenvatinib

China
Institute of Hematology & Blood Diseases Hospital
R&D Kanglin Biotech

Recruiting

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

Transfusion-dependent Beta-Thalassemia

China
AstraZeneca

Recruiting

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

NSCLC

China, United States, United Kingdom, Korea, Republic of, Italy, Hungary, Spain, Vietnam, France, Brazil, Canada, Japan, Taiwan, Germany, Austria, Turkey, India, Peru, Poland, Sweden, Bulgaria, Greece, Mexico, Denmark
Fudan University

Recruiting

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Nasopharyngeal Cancer

China
Merck Sharp & Dohme LLC
Gilead Sciences

Recruiting

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Carcinoma, Non-Small-Cell Lung

China, Poland, Latvia, United States, Taiwan, Australia, Turkey, Germany, Israel, Korea, Republic of, Estonia, Romania, Chile, Italy, Brazil, Greece, Philippines, Canada, Japan, Malaysia, United Kingdom, Lithuania, Thailand, Peru

Search clinical trials for: Antibody Dependent Cellular Cytotoxicity (ADCC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations